Rallybio Corp RLYB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
-
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
-
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
-
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
-
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
-
Rallybio to Present at Upcoming Investor Conferences
-
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
Trading Information
- Previous Close Price
- $1.10
- Day Range
- $1.10–1.14
- 52-Week Range
- $1.08–4.60
- Bid/Ask
- $1.10 / $1.13
- Market Cap
- $46.05 Mil
- Volume/Avg
- 27,558 / 75,881
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 147.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- https://www.rallybio.com
Comparables
Valuation
|
Metric
|
RLYB
|
EWTX
|
TERN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.58 | 5.21 | 2.66 |
Price/Sales | 147.04 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RLYB
|
EWTX
|
TERN
|
|---|---|---|---|
Quick Ratio | 7.29 | 29.79 | 20.57 |
Current Ratio | 7.52 | 30.24 | 21.02 |
Interest Coverage | — | — | — |
Quick Ratio
RLYB
EWTX
TERN
Profitability
|
Metric
|
RLYB
|
EWTX
|
TERN
|
|---|---|---|---|
Return on Assets (Normalized) | −55.00% | −23.23% | −28.87% |
Return on Equity (Normalized) | −60.10% | −24.43% | −30.36% |
Return on Invested Capital (Normalized) | −64.90% | −29.19% | −34.37% |
Return on Assets
RLYB
EWTX
TERN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mfkddgcb | Pkjq | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lhzhkqg | Wbpjlm | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dgsxbvk | Krqsfgd | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rkywzdc | Rrnynq | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Jgwrrvth | Xbfm | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Sbcxmjrx | Thgfj | $29.2 Bil | |||
| Moderna Inc
MRNA
| Flydbbyf | Qjqt | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jjpzfvkb | Clzp | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dbxtpdd | Vknmmw | $13.2 Bil | |||
| Incyte Corp
INCY
| Hjlknqrg | Gprjnmt | $13.0 Bil |
United States